Bafna Pharmaceuticals reported a sharp decline in profitability for the quarter ended June 30, 2026, as net profit fell to ₹7.51 lakh from ₹338.89 lakh in the corresponding period of the previous fiscal year. The Chennai-based pharmaceutical manufacturer saw its revenue from operations drop 23.2% year-on-year to ₹2,658.32 lakh, reflecting broader operational pressures. EBITDA contracted to 9M Rupees from 51M Rupees year-on-year, with the EBITDA margin compressing sharply to 3.31% from 14.64%, underscoring the severity of the margin erosion during the quarter. The Board of Directors approved the unaudited financial results on August 11, 2026, following a review by the Audit Committee.

The steep drop in earnings was driven by a combination of lower top-line performance and persistent cost structures. While total income decreased to ₹2,849.42 lakh from ₹3,521.96 lakh year-ago, total expenses remained relatively high at ₹2,841.91 lakh. This resulted in a pre-tax profit margin that compressed significantly compared to the prior year. The statutory auditors, Brahmayya & Co., issued a limited review report on the financial statements, confirming compliance with Ind AS 34 and SEBI regulations.

Financial Performance Highlights

The following table outlines the key financial metrics for the quarter ended June 30, 2026, compared to previous periods:

Revenue from operations declined to ₹2,658.32 lakh from ₹3,462.40 lakh in Q1FY26. The decline in total expenses of 10.7% was not sufficient to offset the larger revenue drop of 23.2%, leading to severe compression in both operating and net margins. Other income increased to ₹191.10 lakh from ₹59.56 lakh, providing some cushion but failing to prevent the bottom-line collapse.

What the Numbers Show

The divergence between the decline in revenue and the slower decline in expenses highlights fixed-cost rigidity within the business model. While cost of materials consumed dropped to ₹1,431.50 lakh from ₹1,755.78 lakh, employee benefit expenses remained nearly flat at ₹561.63 lakh compared to ₹563.99 lakh year-ago. This suggests that operational leverage is currently working against the company during periods of volume or value contraction. The EBITDA margin contraction from 14.64% to 3.31% year-on-year further illustrates how fixed and semi-fixed costs have disproportionately weighed on profitability as revenues declined. Additionally, finance costs decreased slightly to ₹93.70 lakh, indicating stable debt servicing obligations despite the revenue headwinds.

Regulatory and Legal Disclosures

The filing includes an emphasis of matter regarding ongoing Goods and Services Tax (GST) disputes. The company has received a demand order for ₹235.47 lakh and another order for the recovery of GST refunds amounting to ₹331.09 lakh, including interest and penalties. Bafna Pharmaceuticals has filed an appeal against the demand and obtained a stay on the refund recovery amount through a writ petition before the Madras High Court. Management stated it does not anticipate any adverse financial outcome from these proceedings.

Corporate Actions

The Board also scheduled the 31st Annual General Meeting (AGM) for September 11, 2026, to be held via Video Conferencing/Other Audio-Visual Means. The register of members will remain closed from September 5, 2026, to September 11, 2026, for the purpose of determining dividend entitlements and voting rights. The cut-off date for voting eligibility is set as September 4, 2026.

Promoters of bafna pharmaceuticals have confirmed that no shares of the company were encumbered during the financial year ended March 31, 2026. The disclosures were submitted to the stock exchanges in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulatory filing ensures transparency regarding the pledging or hypothecation of promoter holdings.

Bafna Mahaveer Chand, a promoter of the company, declared on behalf of the Promoter and Promoter Group that no encumbrance of shares was made directly or indirectly in FY26. The confirmation was addressed to BSE Limited and the National Stock Exchange of India Limited. The company’s scrip codes are 532989 on the BSE and BAFNAPH on the NSE.

SRJR Lifesciences LLP, also identified as a promoter, submitted a separate declaration confirming that it did not create any encumbrance over the shares held by the firm during the same period. The disclosure was signed by Upendar Mekala Reddy, Designated Partner of SRJR Lifesciences LLP. The entity provided its LLPIN as AAR-4517.

The following table summarizes the key details of the disclosures:

The submissions were made to the exchanges on April 4, 2026, and April 1, 2026, respectively. Copies of the disclosures were also marked to the Audit Committee and the Company Secretary of Bafna Pharmaceuticals Limited. The company’s registered office is located in Chennai, Tamil Nadu.